Inspection Record

Delta Pharma, Inc. — FDA 483 Findings

US FDAInspected 2022-05-20Published 2022-09-26 5 findingsTraining and personnelAseptic processing and sterility assuranceEquipment and facility

Inspectors Jennifer Lalama · Regan T HarpThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Training and personnel

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

2Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

3Aseptic processing and sterility assurance

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.

4Equipment and facility

Routine calibration of equipment is not performed according to a written program designed to assure proper performance.

5Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

About this record

Extracted automatically from the document US FDA published on 2022-09-26. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Delta Pharma, Inc. company profile — full history US FDA documents, 2022 Go to Findings search